Advertisement
Advertisement

DMRA

D

Damora Therapeutics, Inc. Common Stock

25.36
USD
Sponsored
-0.30
-1.17%
May 01, 16:00 UTC -4
Closed
exchange

After-Market

25.77

+0.41
+1.64%

Damora Therapeutics, Inc. Common Stock Profile

About

Galecto Inc. is a clinical stage biotechnology company with advanced programs in fibrosis and cancer centered on galectin-3 and LOXL2. The Company's pipeline includes an inhaled galectin-3 modulator currently in Phase 2b for the potential treatment of idiopathic pulmonary fibrosis. Galecto Inc. is headquarters in Copenhagen, Denmark.

Info & Links

CEO

Carl Goldfischer

Headquarters

221 Crescent Street Building 23, Suite 105
Boston, MA 02109, DENMARK

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.galecto.com

Auditor

EY Godkendt Revisionspartnerselskab

Share holders

36

Employees

7

Damora Therapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

1.55B

Enterprise Value

1.30B

Enterprise Value/EBITDA(ttm)

-6.15

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

--

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-147.05%

Return on Invested Capital(ttm)

-172.49%

Return on Assets(ttm)

-279.49%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-210.85M

Net Income Available to Common(ttm)

-5.42M

Diluted EPS(ttm)

-12.10

Share Statistics

Beta (5Y Monthly)

1.59

52-Week Change

--

S&P 500 52-Week Change

27.14%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

60.30M

Dividend Yield

0.00%

Float4

53.99M

% Held by Insiders

10.46%

% Held by Institutions

14.20%

Balance Sheet

Total Cash(mrq)

257.62M

Total Cash Per Share(mrq)

4.27

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

12.98%

Quick Ratio(mrq)

12.98%

Book Value Per Share(mrq)

150.52

Cash Flow

Operating Cash Flow Per Share(ytd)

-4.93

Free Cash Flow(ytd)

-6.73M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement